Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC is a research paper published in Journal of Thoracic Oncology (2020). On theSindex it has a DataRank of 6.8. It has been cited 195 times, with 168 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.792
From this paper's citation signal
Citation Network Contribution
6.0
From 134 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 168 citers.
Cancer Prevention and Research Institute of Texas
Grant: RP160668
Additional file 1 of Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
Additional file 1 of Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
Additional file 1 of Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
Additional file 1 of Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
Additional file 1 of Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
Additional file 1 of Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
Additional file 2 of Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
Additional file 2 of Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
Additional file 1 of Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer
Additional file 1 of Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer
Additional file 1 of Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer
Additional file 1 of Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer
Additional file 2 of Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer
Additional file 2 of Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer
Additional file 3 of Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer
Additional file 4 of Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer
Additional file 3 of Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer
Additional file 4 of Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer
Additional file 2 of Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
Additional file 2 of Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma